R
Robert Putnak
Researcher at Walter Reed Army Institute of Research
Publications - 45
Citations - 2467
Robert Putnak is an academic researcher from Walter Reed Army Institute of Research. The author has contributed to research in topics: Dengue virus & Dengue fever. The author has an hindex of 26, co-authored 45 publications receiving 2337 citations.
Papers
More filters
Journal ArticleDOI
Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.
Stephen J. Thomas,Ananda Nisalak,Kathryn B. Anderson,Daniel H. Libraty,Siripen Kalayanarooj,David W. Vaughn,Robert Putnak,Robert V. Gibbons,Richard G. Jarman,Timothy P. Endy +9 more
TL;DR: Findings indicate wide variation in PRNT titer results in response to varied testing conditions, particularly in children experiencing primary and secondary DENV infections.
Journal ArticleDOI
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Katrin Ramsauer,Michael Schwameis,Christa Firbas,Matthias Müllner,Robert Putnak,Stephen J. Thomas,Philippe Desprès,Erich Tauber,Bernd Jilma,Frédéric Tangy +9 more
TL;DR: The live recombinant measles-virus-based chikungunya vaccine had good immunogenicity, even in the presence of anti-vector immunity, was safe, and had a generally acceptable tolerability profile.
Journal ArticleDOI
Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain).
TL;DR: The complete nucleotide sequence, with the exception of about 7 nt at the 5'-noncoding region, of this RNA genome derived from several cDNA clones of the dengue virus type 2 (DEN-2) RNA is described.
Journal ArticleDOI
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Robert R. Edelman,Steven S. Wasserman,Sacared A Bodison,Robert Putnak,Kenneth H. Eckels,Douglas B. Tang,Niranjan Kanesa-thasan,David W. Vaughn,Bruce L. Innis,Wellington Sun +9 more
TL;DR: Seven formulations met the serologic criteria required for an expanded trial, and three were sufficiently attenuated clinically to justify further testing and would be considered for an expand Phase II trial in the future.
Journal ArticleDOI
Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys
Robert Putnak,David A. Barvir,Jeanne Burrous,Doria R. Dubois,Valerie M. D'Andrea,Charles H. Hoke,Jerald C. Sadoff,Kenneth H. Eckels +7 more
TL;DR: The feasibility of a purified, inactivated dengue (DEN) vaccine made in Vero cells was explored and the virus retained its antigenicity and was immunogenic in mice and rhesus monkeys, in which it elicited high titers of DEN-2 virus-neutralizing antibody.